BioCryst (BCRX) Receives Order for 10K Courses of Peramivir from U.S. for H1N1, Worth $22.5M

November 5, 2009 7:07 AM EST

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) received an initial order for 10,000 courses of intravenous (i.v.) peramivir (600 mg once-daily for five days) with a value of $22.5 million under a newly issued contract with the Department of Health and Human Services (HHS). On November 4, BioCryst shipped the entire order from existing i.v. peramivir inventory to HHS.

"BioCryst is pleased to deliver this initial U.S. Government order for peramivir for use under the Emergency Use Authorization, or EUA, to treat hospitalized adult and pediatric influenza patients who may benefit from peramivir," said Jon P. Stonehouse, President and Chief Executive Officer at BioCryst. "We expect to complete production of approximately 120,000 additional courses of i.v. peramivir by the end of December, and we are prepared to produce more if required to meet orders for the U.S. or other governments. BioCryst has been in contact with a number of governments around the world that are assessing i.v. peramivir for critically ill influenza patients.

Related Categories

FDA
Momentum Movers
Trader Talk

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?